Evidence map›Paper›PMID 42550827›Full record

ArticlePLoS neglected tropical diseases2026

Development of a predictive model for meglumine antimoniate treatment failure in patients with cutaneous leishmaniasis: Aretrospective cohort study.

Susana Ríos-Echavarría, Gilma Hernández Herrera, Hector Ivan García García, Liliana López-Carvajal, Lina Maria Serna-Higuita

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Susana Ríos-EchavarríaGroup of Clinical Trials PECET, University of Antioquia, Medellín, Colombia.
Gilma Hernández HerreraAcademic Group of Clinical Epidemiology (GRAEPIC), University of Antioquia, Medellín, Colombia.
Hector Ivan García GarcíaAcademic Group of Clinical Epidemiology (GRAEPIC), University of Antioquia, Medellín, Colombia.
Liliana López-CarvajalGroup of Clinical Trials PECET, University of Antioquia, Medellín, Colombia.
Lina Maria Serna-HiguitaDepartment of Clinical Epidemiology and Applied Biostatistics, University Hospital Tübingen, Tübingen, Germany.ORCID https://orcid.org/0000-0001-5182-8295

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough alternative therapies for cutaneous leishmaniasis (CL) are available, systemic meglumine antimoniate (MA) remains the first-line treatment in many endemic regions. Its use is nevertheless associated with serious adverse effects and a high risk of treatment failure (TF). This study aimed to identify clinical and sociodemographic risk factors for TF following systemic MA therapy, which may enhance therapeutic decision-making and improve clinical outcomes. METHODOLOGY: We evaluated a retrospective cohort of 296 patients with CL treated with MA between 2007 and 2024. A multivariable logistic regression model was performed using candidate variables selected via clinical relevance, biological plausibility, stepwise selection and least absolute shrinkage and selection operator (Lasso) regression. Model performance was assessed through discrimination, calibration, and internal validation. Results were reported as odds ratios, 95% confidence intervals and p-values. PRINCIPAL

findingsAll included patients received first line MA therapy and completed at least six months of follow-up. Independent predictors associated with TF were age, occupational activity, size, number and anatomical location of lesions, clinical form, regional lymphadenopathy, and prior history of leishmaniasis. The final model showed moderate overall performance with a Hosmer-Lemeshow p value = 0.667, AUC = 0.691, and a Brier score of 22.8. Internal validation yielded a Harrel C = 0.608.

conclusionsThe present study demonstrates an association between TF and socio-demographic, clinical variables. Identifying these risk factors may support clinical decision-making and contribute to optimizing treatment outcomes.

Indexed as

Antiprotozoal AgentsLeishmaniasis, CutaneousMeglumine AntimoniateAdolescentAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTreatment FailureYoung AdultAntiprotozoal AgentsMeglumine Antimoniate

Identifiers

PMID42550827
PMCPMC13436726

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.